Improving the care pathway for patients suffering from respiratory diseases
Biosency aims to improve the management of patients with cardio-respiratory insufficiency by offering a disruptive digital solution, integrating the analysis of clinical data, to optimise the monitoring of patients ' progress at home and to facilitate the coordination of healthcare professionals.
Our tasks :
- Developing the best remote monitoring solutions
- Developing a solution for predicting COPD exacerbations
- Host and distribute integrated services to exploit the full potential of real-life data for clinical, research or statistical purposes
Our R&D department constantly thrives to enrich the set of cardio-respiratory parameters monitored by our solution and expand our preventive solution by introducing a reliable predictive diagnosis for COPD exacerbation.
• Regular check-ups
• Follow-up of patients at risk
- Real time and real life data
Strategic partnership with ResMed
A new major step in our development has been taken with the signature of a strategic partnership with ResMed, the world leader in innovative solutions for the treatment of respiratory disorders. ResMed will distribute our Bora care® remote monitoring solution in France, North Africa and some European countries to healthcare professionals who treat patients suffering from respiratory failure.
Marie Pirotais Digital Breton of the Year
We are proud to announce that Marie Pirotais was awarded the title of Breton Digital Woman of the Year on behalf of Biosency on Thursday 10th February on the set of Tébéo & Tébésud during the Awards for Digital Talent in Brittany organised by Épopée and West Web Valley.
Inclusion of the first patient in the e-meuse study
Biosency, winner of the Territoire Innovation award, is participating in the first large-scale experiment in remote monitoring of patients suffering from sleep apnea or COPD. For three and a half years, 400 patients will be monitored remotely in order to assess the benefits of using connected devices to manage these chronic respiratory diseases.
Yann Le Guillou : Silver Award in the category “AMBA Best Start-Up of the Year 2021”
In the highly contested competition, we are proud to announce that Dr Yann Le Guillou has been awarded on behalf of Biosency the Silver Award in the category “AMBA Best Start-Up of the Year 2021”.
Biosency joins Boehringer Ingelheim's SYNAPSE accelerator
Launched in January 2019 by Boehringer Ingelheim, "Synapse" is the first digital health accelerator.
Winner of the Health Innovation Coalition
Biosency is one of the first three winners of the Health Innovation Coalition, a coalition of public and private partners mobilised to provide patients suffering from chronic diseases with innovative and disruptive digital solutions as quickly as possible. In this context, the pharmaceutical companies AstraZeneca and GSK are providing institutional support for the deployment of Biosency's Bora connect® remote monitoring system for patients with respiratory insufficiency.
1st patients followed by Bora connect®.
Commercial launch of Bora connect® remote monitoring solution. Equipment of the first patients with cardiorespiratory insufficiency
Obtaining the CE DM mark and commercial launch of Bora connect®.
Obtaining certification is a key step in the development of Biosency because it authorizes the sales of this first service which begins in March 2020. The CE MD certificate, issued by the notified body BSI certifies the entire remote monitoring service. See the press release : https://bit.ly/2VL8kIz
Winner of the i-nov trophy
Biosency is the winner of the "i-Nov" innovation competition in the "deeptech" category. i-nov is a support program financed by the “Programme d'Investissements d'Avenir” (PIA), that aims to select innovation projects with particularly strong potential for the French economy.
Compliance of the Bora band
March 2019, 2015
Bora band® complies with the following standards: ISO 80601-2-61: Performance validated by a clinical study ISO 80601-2-56 clause 201.101.2: Accuracy of skin temperature validated by a laboratory IEC 60601-1, IEC 60601-1-2 and IEC 60601-1-11: Electrical safety and EMC testing ETSI EN 300 328 V2.1.1 and EN 62479: EMC standard for radio equipment and services IEC 60601-1-1: Home use validation IEC 60529-1 - IP64: No dust ingress, water resistant SO 10993-5, and 10993-11: Cytotoxicity, sensitisation and irritation to assess permanent contact with silicone, polycarbonate, carbon black and stainless steel with intact skin. ISO 60601-1-6: General requirements for safety - Collateral standard: Ease of use
Biosency raises 1.5 Million €, from its historic investors, renewing their support and trust in the device.
Winner of the I-Lab trophy
Biosency wins the 20th I-Lab contest, the flagship national French contest for creators of innovative technology companies. Organized by the French Ministry of Research and Innovation, it rewards the best deeptech projects.
Manufacture of the first pre-series
The first industrial products have been manufactured by our subcontractor (ISO 13485 certification) in the aim of validating the performances of our device. This is a mandatory step to obtain the CE MD certification. Manufacturing is made in Bretagne, as we can ensure the mastery and the reliability of our process.
Biosency raises 800 k€ from GO CAPITAL Amorçage II, Crédit Agricole Ille et Vilaine Expansion and private investors.
First prototypes and user tests
It is essential for Biosency to involve users at every stage of our development. The ergonomics and ease of use of Bora band® and Bora connect® have been specifically designed, tested and validated in collaboration with COPD patients, pulmonologists, and home health care providers to enable daily and long-term use.
Agreement on collaboration with ECA
Biosency signs a collaboration agreement with CEA Leti's DTBS department (Department of Micro-Technologies for Biology and Health) for the development of Bora band®.
Creation of the company
Biosency was founded in July 2017 by Marie Pirotais, Yann Le Guillou et Gilles Giannoli, supported by a scientific board of 6 pulmonolgists experts.